肝肉瘤样癌（HSC）的特点是侵袭性行为和预后不良。截至目前，尚未建立普遍认可的 HSC 标准治疗方法。在此，我们描述了一名 60 岁患者被诊断患有 HSC，术后出现多发转移的病例。由于程序性细胞死亡蛋白 1 (PD-1) 的显着表达，该个体接受了信迪利单抗单一疗法，为期 12 个月。根据该方案，制定了包含安罗替尼和信迪利单抗的协同治疗方法，最终产生了随后 11 个月的有效治疗反应。在整个治疗过程中，患者的生活质量始终令人满意。这种特殊的治疗策略不仅增强了 PD-1 抑制剂在 HSC 管理领域的功效，更重要的是，表明酪氨酸激酶抑制剂 (TKI) 可能会抵消 PD-1 拮抗剂的耐药性，从而为 HSC 治疗提供潜在的增强治疗范例。 HSC.© 2023。作者获得 Springer-Verlag GmbH 德国（Springer Nature 旗下公司）的独家许可。

Hepatic sarcomatoid carcinoma (HSC) is characterized by its aggressive behavior and poor prognosis. As of now, no universally endorsed standard therapeutic approaches for HSC have been established. Herein, we describe the case of a 60-year-old individual diagnosed with HSC, subsequently presenting with multiple metastases postoperatively. Owing to the pronounced expression of programmed cell death protein 1 (PD-1), the individual was subjected to monotherapy utilizing sintilimab for a duration spanning 12 months. Following this regimen, a synergistic treatment approach comprising both anlotinib and sintilimab was instituted, culminating in an ensuing 11 months of efficacious therapeutic response. Throughout the course of treatment, the patient's quality of life remained satisfactory. This particular therapeutic strategy not merely reinforces the efficacy of PD-1 inhibitors in the realm of HSC management, but more pivotally, suggests that tyrosine kinase inhibitors (TKIs) might counteract resistance to PD-1 antagonists, thus offering a potentially augmented treatment paradigm for HSC.© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.